A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
NCT ID: NCT00337090
Last Updated: 2013-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1108 participants
INTERVENTIONAL
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01604928
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
NCT00966004
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT00840645
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM178
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astellas Pharma
Role: STUDY_CHAIR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
3 Sites
Antwerp, , Belgium
2 Sites
Brussels, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Brno, , Czechia
Mělník, , Czechia
Ostrava, , Czechia
3 Sites
Prague, , Czechia
Ústí nad Labem, , Czechia
Zlín, , Czechia
Holbæk, , Denmark
Kolding, , Denmark
Roskilde, , Denmark
2 Sites
Nantes, , France
2 Sites
Paris, , France
Bad Ems, , Germany
Bamberg, , Germany
Bautzen, , Germany
Berlin, , Germany
Dresden, , Germany
Frankfurt, , Germany
Hagenow, , Germany
Halle, , Germany
Hamburg, , Germany
Koblenz, , Germany
Leipzig, , Germany
München, , Germany
Radebeul, , Germany
Trier, , Germany
Uetersen, , Germany
3 Sites
Athens, , Greece
Pátrai, , Greece
Miskolc, , Hungary
Nyíregyháza, , Hungary
Pécs, , Hungary
Sopron, , Hungary
Szeged, , Hungary
Tatabánya, , Hungary
Catanzaro, , Italy
Milan, , Italy
Modena, , Italy
Padua, , Italy
Roma, , Italy
Sassari, , Italy
Torino, , Italy
Udine, , Italy
Varese, , Italy
Amsterdam, , Netherlands
Apeldoorn, , Netherlands
Arnhem, , Netherlands
Eindhoven, , Netherlands
Enschede, , Netherlands
Maastricht, , Netherlands
Bergen, , Norway
Oslo, , Norway
Tønsberg, , Norway
Bialystok, , Poland
Katowice, , Poland
Kielce, , Poland
Lublin, , Poland
3 Sites
Warsaw, , Poland
3 Sites
Wroclaw, , Poland
7 Sites
Moscow, , Russia
3 Sites
Saint Petersburg, , Russia
2 Sites
Barcelona, , Spain
Bilbao, , Spain
2 Sites
Madrid, , Spain
Manacor, , Spain
Miranda de Ebro, , Spain
San Juan de Alica, , Spain
Seville, , Spain
Vigo, , Spain
Gothenburg, , Sweden
2 Sites
Stockholm, , Sweden
Birmingham, , United Kingdom
Blackburn, , United Kingdom
Chichester, , United Kingdom
Croydon, , United Kingdom
London, , United Kingdom
Reading, , United Kingdom
Sheffield, , United Kingdom
Southampton, , United Kingdom
Swansea, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023 May 9;5(5):CD003781. doi: 10.1002/14651858.CD003781.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
178-CL-044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.